Sanara MedTech Inc. Announces Exclusive License and Distribution Agreement with, and Minority Investment in, Biomimetic Innovations Ltd

By Dr. Matthew Watson

OsStic® and related technologies represent differentiated solutions that address an estimated 100,000+ procedures in the U.S. annually(1); arrangement leverages Sanara’s existing call points and commercial infrastructure, and complements Sanara’s existing surgical portfolio

The rest is here:
Sanara MedTech Inc. Announces Exclusive License and Distribution Agreement with, and Minority Investment in, Biomimetic Innovations Ltd

Related Post

• Rakovina Therapeutics Announces Listing on Frankfurt Stock Exchange - January 31st, 2025
• Aclaris Therapeutics Announces Formation of New Scientific Advisory Board - January 31st, 2025
• PacBio to Report Fourth Quarter 2024 Financial Results on February 13, 2025 - January 31st, 2025
• Cidara Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference - January 31st, 2025
• Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference - January 31st, 2025
• Avid Stockholders Approve Transaction with GHO and Ampersand - January 31st, 2025
• Ardelyx to Report Full Year and Fourth Quarter 2024 Financial Results on February 20, 2025 - January 31st, 2025
• Portage Biotech Announces Completion of $2.15 Million Private Financing - January 31st, 2025
• Diag-Nose.io, Graduate of Stanford EENT Innovation, Closes Oversubscribed $2M Seed Round to Transform Respiratory Care with AI-Driven Precision... - January 31st, 2025
• Diag-Nose.io Opens Houston Office following oversubscribed $2M Seed Round to Measure Respiratory Treatment Success Using Proteomics & AI - January 31st, 2025
• Diag-Nose.io Expands to Bethlehem, PA, Following Oversubscribed $2M Seed Round Funding to Revolutionize Respiratory Diagnostics - January 31st, 2025
• Diag-Nose.io, Graduate of CDL-Seattle, Closes Oversubscribed $2M Seed Round to Transform Respiratory Care with AI-Driven Precision Medicine - January 31st, 2025
• Telix Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform - January 31st, 2025
• BioSyent Declares First Quarter 2025 Dividend - January 31st, 2025
• Tarsus to Participate in Upcoming Investor Conferences - January 31st, 2025
• Ryoncil® Commercial Launch Update and Product Pipeline - January 31st, 2025
• Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024 - January 31st, 2025
• Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2024 - January 31st, 2025
• Press Release: Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for... - January 31st, 2025
• Ultimovacs ASA Reports Fourth Quarter 2024 Financial Results and Provides General Business Update - January 31st, 2025
• Shuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma - January 22nd, 2025
• Nacuity Pharmaceuticals Granted U.S. FDA Fast Track Designation for NPI-001 (N-acetylcysteine amide) Tablets for the Treatment of Retinitis Pigmentosa - January 22nd, 2025
• Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology - January 22nd, 2025
• Welcoming Victor Bornsztejn as Senior Vice President of Commercial - January 22nd, 2025
• Scilex Holding Company Announces that Its Note Holders Intend to Participate in the Funding and Licensing of Gloperba® Ex-U.S. Commercialization... - January 22nd, 2025
• Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas - January 22nd, 2025
• Scilex Holding Company Announces Extension of the Maturity Date of its Secured Promissory Note Issued to Oramed Pharmaceuticals Inc. to December 31,... - January 22nd, 2025
• RS BioTherapeutics Announces Positive Anti-Inflammatory and Anti-Fibrotic Effects of Lead Compound in Human Lung Tissue - January 22nd, 2025
• Scilex Holding Company Announces that It Regains Nasdaq Compliance Under Listing Rule 5250(c)(1) - January 22nd, 2025
• Pharming Group to convene Extraordinary General Meeting of Shareholders - January 22nd, 2025
• BioAdaptives Announces FINRA Approval of a Dividend for Common Stock Shareholders - January 22nd, 2025
• Sanara MedTech Inc. Expands Executive Leadership Team with New Appointments - January 22nd, 2025
• Sanara MedTech Inc. Reports Unaudited Preliminary Results for the Fourth Quarter and Full Year 2024 - January 22nd, 2025
• NurExone Secures C$1.2 Million through Warrant Exercises and Completion of Private Placement and Appoints New R&D Director - January 22nd, 2025
• Adagene to Announce Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO... - January 22nd, 2025
• Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in... - January 22nd, 2025
• Press Release: Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible... - January 22nd, 2025
• ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI - January 22nd, 2025
• Roche receives FDA clearance with CLIA waiver for cobas® liat molecular tests to diagnose sexually transmitted infections at the point of care - January 22nd, 2025
• Apellis Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare Conference - January 14th, 2025
• VIVUS Shares Progress on Pipeline and Key Program Milestones During the 43rd Annual J.P. Morgan Healthcare Conference 2025 - January 14th, 2025
• Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities - January 14th, 2025
• Artelo Biosciences Announces Successful Completion of First Cohort in a Phase 1 Study of ART26.12 - January 14th, 2025
• Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones - January 14th, 2025
• ProMIS Neurosciences Issues Letter to Shareholders - January 14th, 2025
• BridgeBio Announces Commercial Progress, Program Updates, and 2025 Milestones - January 14th, 2025
• OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer - January 14th, 2025
• Correction: GUERBET : Financial agenda for 2025 - January 14th, 2025
• Micron Biomedical Wins $2 Million BARDA Competition for Its Collaboration with Zipcode Bio to Develop mRNA-Based Broad Protecting Flu Vaccine Without... - January 14th, 2025
• Telix Presentation to the 43rd Annual J.P. Morgan Healthcare Conference - January 14th, 2025
• Harvard Bioscience, Inc. to Participate in the Sidoti Micro Cap Conference - January 14th, 2025
• Nxera Pharma Provides Update on Neurocrine’s Progress with its Partnered Muscarinic Agonist Portfolio - January 14th, 2025
• FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s... - January 14th, 2025
• Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial - January 14th, 2025
• HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC - January 14th, 2025
• Sandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd Annual J.P. Morgan Healthcare Conference - January 14th, 2025
• Idorsia publishes an invitation to a bondholder meeting - January 14th, 2025
• Vivoryon Therapeutics N.V. Provides R&D-Update Further Strengthening Development Pipeline in Kidney Disease - January 14th, 2025
• Santhera Receives Positive Recommendation from Scottish Medicines Consortium for the Use of AGAMREE® (Vamorolone) in Duchenne Muscular Dystrophy... - January 14th, 2025
• Certara to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - January 5th, 2025
• Tilray Brands Moves Earnings Date to January 10, 2025, in Observance of the National Day of Mourning - January 5th, 2025
• ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Lonigutamab - January 5th, 2025
• SpringWorks Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - January 5th, 2025
• Eton Pharmaceuticals Advances Its Commitment to Rare Disease with the Acquisition of Galzin® - January 5th, 2025
• Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025 - January 5th, 2025
• Madrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - January 5th, 2025
• Avadel Pharmaceuticals to Provide a Corporate Update and Preliminary Fourth Quarter and Full Year 2024 Financial Highlights on January 8 - January 5th, 2025
• Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar - January 5th, 2025
• Energroup Holdings Corp (OTC: ENHD) to Acquire Cocannco Inc. - January 5th, 2025
• VALNEVA Declaration of shares and voting rights: December 31, 2024 - January 5th, 2025
• Genmab to Present at the 43rd Annual J.P. Morgan Healthcare Conference - January 5th, 2025
• Procaps Group Receives Additional Delinquency Letter - January 5th, 2025
• Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - January 5th, 2025
• BriaCell Announces Rescheduling of its Annual General Meeting of Shareholders to February 5, 2025 - January 5th, 2025
• Rakovina Therapeutics to Connect with Industry Leaders During 43rd Annual J.P. Morgan Healthcare Conference Week - January 5th, 2025
• Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - January 5th, 2025
• BriaCell Announces Proposed Effective Date of Share Consolidation - January 5th, 2025
• PharmaTher Announces Grant of Stock Options - January 5th, 2025
• Oculis Publishes Notification of Major Changes in Voting Rights - January 5th, 2025
• Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment - December 27th, 2024

Global News Feed Comments Off on Sanara MedTech Inc. Announces Exclusive License and Distribution Agreement with, and Minority Investment in, Biomimetic Innovations Ltd | January 22nd, 2025

About... Dr. Matthew Watson

Categories

• Bone Marrow Stem Cells (2,975)
• Cardiac Stem Cells (1,276)
• Global News Feed (3,435)
• Integrative Medicine (105)
• IPS Cell Therapy (474)
• Nano medicine (2)
• Regenerative Medicine (44)
• Skin Stem Cells (2,200)
• Spinal Cord Stem Cells (953)
• Stem Cell Therapy (528)

Archives

Recommended Sites

• California Stem Cell Research
• Cord Blood Banking
• Gene Therapy Breakthroughs
• Immortality Medicine
• Medical School Review
• Nano Technology American Physicians
• Videos Of Stem Cell Therapy